NCT02941679View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

April 30, 2018

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

HCP1202

Hanmi Pharmaceutical. Co., Ltd.

DRUG

HGP1011

Boehringer Ingelheim

DRUG

HCP0910

GlaxoSmithKline

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02941679 - Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients | Biotech Hunter | Biotech Hunter